SMi's 6th annual Orphan Drugs and Rare Diseases event will be taking place in Europe's largest pharmaceutical market, Berlin on 15th - 16th May 2017.
Rare diseases have long been under researched, with many unaware that such conditions even existed. However recent advancements within the orphan drugs landscape has resulted in a significant growth, with the market expected to reach a record breaking $191 billion by 2019. Conversely, there cannot be success without challenges.
With Germany currently possessing one of the toughest pricing mechanisms and policies in Europe, this two day conference will endeavor to establish an interactive platform exploring how payers, pharma, biotech and patient organisations are preparing to participate and leverage the rapidly growing orphan drugs and rare diseases market.
Massimo Bertelli, Country Manager, Aegerion Pharmaceuticals
Alastair Kent, Market Research Manager, Institute of Pharmaceutical Research and Technology
Richard Porter, Chief Operating Officer, Therachon AG
Peter Ramge, Senior Global Product Manager, Novo Nordisk
Tony Zbeidy, General Manager Middle East and North Africa, Orphan Europe
Jama Nateqi, Co-Founder, SYMPTOMA
Cecile De Coster, Associate Directory, Regulatory Affairs, Alexion Pharma GmbH
Carol McCudden, Patient Ambassador, ATAXIA UK
Exchange knowledge and best practices on all relevant issues related to the rare disease environment
Learn strategies on defending the pricing of orphan products and how to establish a foundation for reimbursement
Hear Alexion discuss criteria, comparison and case studies for US and EU regulatory landscapes
Circulate the most relevant findings within the rare disease environment to all relevant stakeholders
Listen to global case studies from Aegerion and Orphan Europe
Discover a new business model for developing rare diseases treatments
Register at www.orphandrugs-event.com/evvnt
Book by 31 Jan: GBP 1099
Book 28 Feb: GBP 1299
Book 31 Mar: GBP 1399
Standard Price: GBP 1499
Speakers: Aegerion Pharmaceuticals, Institute of Pharmaceutical Research and Technology, Therachon AG, Novo Nordisk, Orphan Europe, SYMPTOMA, Alexion Pharma GmbH, ATAXIA UK and many more
Sign in to add slides, notes or videos to this session